IMCL - ImmunoClin Corporation

Other OTC - Other OTC Delayed Price. Currency in USD
0.000000 (0.000000%)
At close: 3:22PM EDT
Stock chart is not supported by your current browser
Previous Close0.159277
Bid0.000000 x 0
Ask0.000000 x 0
Day's Range0.159277 - 0.159277
52 Week Range0.159277 - 0.159277
Avg. VolumeN/A
Market CapN/A
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • PR Newswire8 months ago

    Spotlight Innovation Commences Part 2 of Phase I Cancer Trial

    URBANDALE, Iowa, March 10, 2017 /PRNewswire/ -- Spotlight Innovation Inc. (STLT) today announced that its subsidiary Celtic Biotech has begun Part 2 of its Phase I dose escalation safety study, Crotoxin in Patients with Advanced Cancer using an Intravenous Route of Administration. ImmunoClin Ltd., a company specializing in clinical development, is the contract research organization (CRO) overseeing the study conduct. Dr. Gil-Delgado is a member of the American Society of Clinical Oncology (ASCO).

  • We're sorry this is all we were able to find about this topic.